Gabelli Funds LLC Sells 6,990 Shares of Solventum Corporation $SOLV

Posted by Stanley Muller on May 24th, 2026

Gabelli Funds LLC lowered its position in shares of Solventum Corporation (NYSE:SOLV – Free Report) by 36.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,987 shares of the company’s stock after selling 6,990 shares during the quarter. Gabelli Funds LLC’s holdings in Solventum were worth $950,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in Solventum by 5.3% during the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after acquiring an additional 867,837 shares during the last quarter. Independent Franchise Partners LLP boosted its position in Solventum by 27.2% during the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after acquiring an additional 2,758,174 shares during the last quarter. State Street Corp boosted its position in Solventum by 1.8% during the third quarter. State Street Corp now owns 6,220,271 shares of the company’s stock valued at $454,080,000 after acquiring an additional 112,261 shares during the last quarter. Davis Selected Advisers boosted its position in Solventum by 12.7% during the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock valued at $492,880,000 after acquiring an additional 702,461 shares during the last quarter. Finally, Boston Partners boosted its position in Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after acquiring an additional 959,543 shares during the last quarter.

Solventum Price Performance

Shares of NYSE SOLV opened at $76.92 on Friday. The firm’s 50-day moving average price is $68.68 and its 200-day moving average price is $74.77. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20. The firm has a market capitalization of $13.32 billion, a P/E ratio of 9.43, a P/E/G ratio of 1.19 and a beta of 0.59. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the prior year, the business earned $1.34 earnings per share. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities research analysts anticipate that Solventum Corporation will post 6.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Solventum

In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the acquisition, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. The trade was a 41.39% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.24% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on SOLV shares. KeyCorp upped their price objective on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Wells Fargo & Company dropped their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 6th. Piper Sandler dropped their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Eight investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.25.

Check Out Our Latest Stock Report on SOLV

Solventum Profile

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.